"We observed a decline among children in the number of depression visits with an antidepressant prescribed after the FDA advisory,
a trend that seemed to parallel an overall decrease in depression visits," authors Shih-Yin Chen, Ph.D., and Sengwee Toh,
Sc.D., wrote. "When we further assessed the trend in terms of proportion, the likelihood of prescribing an antidepressant
among visits with a diagnosis of depression among children remained relatively stable at approximately 65 percent just before
and after the advisory.... These findings suggest that the FDA advisory might have led to fewer numbers of depression visits
overall and of depression visits with an antidepressant prescribed. But even with this decline, if children were actually
diagnosed as having depression, they might not have been any less likely to have been prescribed an antidepressant after the
advisory than they had been before it."